Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41

P Rastogi, G Tang, S Hassan, CE Geyer Jr… - Breast Cancer Research …, 2023 - Springer
Background The primary aim of this randomized neoadjuvant trial in operable, HER2-
positive breast cancer, was to determine the efficacy on pathologic complete response …
被引用次数：6 相关文章

Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41

P Rastogi, G Tang, S Hassan, CE Geyer… - Breast Cancer …, 2023 - search.proquest.com
Background The primary aim of this randomized neoadjuvant trial in operable, HER2-
positive breast cancer, was to determine the efficacy on pathologic complete response …

Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41

P Rastogi, G Tang, S Hassan, CE Geyer Jr, CA Azar… - 2023 - pubmed.ncbi.nlm.nih.gov
Background The primary aim of this randomized neoadjuvant trial in operable, HER2-
positive breast cancer, was to determine the efficacy on pathologic complete response …

Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41.

P Rastogi, G Tang, S Hassan, CE Geyer Jr… - … Cancer Research and …, 2023 - europepmc.org
Background The primary aim of this randomized neoadjuvant trial in operable, HER2-
positive breast cancer, was to determine the efficacy on pathologic complete response …